Skip to main content
SpringerLink
Log in
SpringerLink
Log in

In Vitro Testing for Direct Immunotoxicity: State of the Art

  • Protocol
  • First Online:
Immunotoxicity Testing

Part of the book series: Methods in Molecular Biology™ ((MIMB,volume 598))

Abstract

Immunotoxicity is defined as the toxicological effects of xenobiotics including pharmaceuticals on the functioning of the immune system and can be induced in either direct or indirect ways. Direct immunotoxicity is caused by the effects of chemicals on the immune system, leading to immunosuppression and subsequently to reduced resistance to infectious diseases or certain forms of nongenotoxic carcinogenicity.

In vitro testing has several advantages over in vivo testing, such as detailed mechanistic understanding, species extrapolation (parallelogram approach), and reduction, refinement, and replacement of animal experiments. In vitro testing for direct immunotoxicity can be done in a two-tiered approach, the first tier measuring myelotoxicity. If this type of toxicity is apparent, the compound can be designated immunotoxic. If not, the compound is tested for lymphotoxicity (second tier). Several in vitro assays for lymphotoxicity exist, each comprising specific functions of the immune system (cytokine production, cell proliferation, cytotoxic T-cell activity, natural killer cell activity, antibody production, and dendritic cell maturation). A brief description of each assay is provided. Only one assay, the human whole blood cytokine release assay, has undergone formal prevalidation, while another one, the lymphocyte proliferation assay, is progressing towards that phase.

Progress in in vitro testing for direct immunotoxicity includes prevalidation of existing assays and selection of the assay (or combination of assays) that performs best. To avoid inter-species extrapolation, assays should preferably use human cells. Furthermore, the use of whole blood has the advantage of comprising multiple cell types in their natural proportion and environment. The so-called “omics” techniques provide additional mechanistic understanding and hold promise for the characterization of classes of compounds and prediction of specific toxic effects. Technical innovations such as high-content screening and high-throughput analysis will greatly expand the opportunities for in vitro testing.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Protocol
USD 49.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Snodin DJ (2004) Regulatory immunotoxicology: does the published evidence support mandatory nonclinical immune function screening in drug development? Regul Toxicol Pharmacol 40:336–355

    Article  CAS  PubMed  Google Scholar 

  2. Balls M, Goldberg AM, Fentem JH et al (1995) The three Rs: the way forward: the report and recommendations of ECVAM Workshop 11. Altern Lab Anim 23:838–866

    PubMed  Google Scholar 

  3. Gennari A, Ban M, Braun A et al (2005) The use of in vitro systems for evaluating immunotoxicity: the report and recommendations of an ECVAM workshop. J Immunotoxicol 2:61–83

    Article  PubMed  Google Scholar 

  4. Carfi’ M, Gennari A, Malerba I et al (2007) In vitro tests to evaluate immunotoxicity: a preliminary study. Toxicology 229:11–22

    Article  PubMed  Google Scholar 

  5. International Programme on Chemical Safety (IPCS) (1996) Principles and methods for assessing direct immunotoxicity associated with exposure to chemicals. Environmental health criteria 180. World Health Organization, Geneva

    Google Scholar 

  6. Pessina A, Albella B, Bueren J et al (2001) Prevalidation of a model for predicting acute neutropenia by colony forming unit granulocyte/macrophage (CFU-GM) assay. Toxicol In Vitro 15:729–740

    Article  CAS  PubMed  Google Scholar 

  7. Pessina A, Albella B, Bayo M et al (2003) Application of the CFU-GM assay to predict acute drug-induced neutropenia: an international blind trial to validate a prediction model for the maximum tolerated dose (MTD) of myelosuppressive xenobiotics. Toxicol Sci 75:355–367

    Article  CAS  PubMed  Google Scholar 

  8. Vandebriel RJ, Garssen J, Van Loveren H (1995) Methods in immunotoxicology. In: Phillips MI, Evans D (eds) Neuroimmunology. Methods in Neuroscience, vol 24. Academic, San Diego, pp 151–169

    Google Scholar 

  9. Langezaal I, Hoffmann S, Hartung T, Coecke S (2002) Evaluation and prevalidation of an immunotoxicity test based on human whole-blood cytokine release. Altern Lab Anim 30:581–595

    CAS  PubMed  Google Scholar 

  10. Hartung T, Wendel A (1996) Detection of pyrogens using human whole blood. In Vitro Toxicol 9:353–359

    CAS  Google Scholar 

  11. Smialowicz RJ (1995) Immune function testing for the identification and characterisation of immunotoxicity in rodents. Hum Exp Toxicol 14:135–136

    Article  CAS  PubMed  Google Scholar 

  12. House RV, Thomas PT (1995) In vitro induction of cytotoxic T lymphocytes. In: Burleson GR, Dean JH, Munson AE (eds) Methods in immunotoxicology, Wiley-Liss, NY, pp 159–171

    Google Scholar 

  13. Cederbrant K, Marcusson-Ståhl M, Condevaux F, Descotes J (2003) NK-cell activity in immunotoxicity drug evaluation. Toxicology 185:241–250

    Article  CAS  PubMed  Google Scholar 

  14. Kane KL, Ashton FA, Schmitz JL, Folds JD (1996) Determination of natural killer cell function by flow cytometry. Clin Diagn Lab Immunol 3:295–300

    CAS  PubMed  Google Scholar 

  15. Marcusson-Ståhl M, Cederbrant K (2003) A flow-cytometric NK-cytotoxicity assay adapted for use in rat repeated dose toxicity studies. Toxicology 193:269–279

    Article  PubMed  Google Scholar 

  16. Stewart CC, Cookfair DL, Hovey KM et al (2003) Predictive immunophenotypes: disease-related profile in chronic fatigue syndrome. Cytometry B Clin Cytom 53:26–33

    Article  PubMed  Google Scholar 

  17. Trinchieri G (1989) Biology of natural killer cells. Adv Immunol 47:187–376

    Article  CAS  PubMed  Google Scholar 

  18. Koeper LM, Vohr HW (2009) Functional assays are mandatory for a correct prediction of immunotoxic properties of compounds in vitro. Food Chem Toxicol 47(1):110–118

    Article  CAS  PubMed  Google Scholar 

  19. Mellman I, Steinman RM (2001) Dendritic cells: specialized and regulated antigen processing machines. Cell 106:255–258

    Article  CAS  PubMed  Google Scholar 

  20. Toebak MJ, de Rooij J, Moed H et al (2008) Differential suppression of dendritic cell cytokine production by anti-inflammatory drugs. Br J Dermatol 158:225–233

    CAS  PubMed  Google Scholar 

  21. Ullerås E, Trzaska D, Arkusz J et al (2005) Development of the “Cell Chip”: a new in vitro alternative technique for immunotoxicity testing. Toxicology 206:245–256

    Article  PubMed  Google Scholar 

  22. Ringerike T, Ullerås E, Völker R et al (2005) Detection of immunotoxicity using T-cell based cytokine reporter cell lines (“Cell Chip”). Toxicology 206:257–272

    Article  CAS  PubMed  Google Scholar 

  23. Trzaska D, Zembek P, Olszewski M et al (2005) “Fluorescent Cell Chip” for immunotoxicity testing: development of the c-fos expression reporter cell lines. Toxicol Appl Pharmacol 207(2 Suppl):133–141

    Article  PubMed  Google Scholar 

  24. Wagner W, Walczak-Drzewiecka A, Slusarczyk A et al (2006) Fluorescent Cell Chip a new in vitro approach for immunotoxicity screening. Toxicol Lett 162:55–70

    Article  CAS  PubMed  Google Scholar 

  25. de Longueville F, Bertholet V, Remacle J (2004) DNA microarrays as a tool in toxicogenomics. Comb Chem High Throughput Screen 7:207–211

    PubMed  Google Scholar 

  26. Tugwood JD, Hollins LE, Cockerill MJ (2003) Genomics and the search for novel biomarkers in toxicology. Biomarkers 8:79–92

    Article  CAS  PubMed  Google Scholar 

  27. Steiner G, Suter L, Boess F et al (2004) Discriminating different classes of toxicants by transcript profiling. Environ Health Perspect 112:1236–1248

    Article  CAS  PubMed  Google Scholar 

  28. Waters, M.D. and Fostel, J.M (2004) Toxicogenomics and systems toxicology: aims and prospects. Nat Rev Genet 5:936–948

    Article  Google Scholar 

  29. Burczynski ME, McMillian M, Ciervo J et al (2000) Toxicogenomics-based discrimination of toxic mechanism in HepG2 human hepatoma cells. Toxicol Sci 58:399–415

    Article  CAS  PubMed  Google Scholar 

  30. Thomas RS, Rank DR, Penn SG et al (2001) Identification of toxicologically predictive gene sets using cDNA microarrays. Mol Pharmacol 60:1189–1194

    CAS  PubMed  Google Scholar 

  31. Waring JF, Jolly RA, Ciurlionis R et al (2001) Clustering of hepatotoxins based on mechanism of toxicity using gene expression profiles. Toxicol Appl Pharmacol 175:28–42

    Article  CAS  PubMed  Google Scholar 

  32. Hamadeh HK, Bushel PR, Jayadev S, et al (2002) Gene expression analysis reveals chemical-specific profiles. Toxicol Sci 67:219–231

    Article  CAS  PubMed  Google Scholar 

  33. Baken KA, Pennings JL, Jonker MJ et al (2008) Overlapping gene expression profiles of model compounds provide opportunities for immunotoxicity screening. Toxicol Appl Pharmacol 226:46–59

    Article  CAS  PubMed  Google Scholar 

  34. Patterson RM, Germolec DR (2006) Gene expression alterations in immune system pathways following exposure to immunosuppressive chemicals. Ann N Y Acad Sci 1076:718–727

    Article  CAS  PubMed  Google Scholar 

  35. Baken KA, van Loveren H, Pennings JL et al (2006) Gene expression profiling of Bis(tri-n-butyltin)oxide (TBTO)-induced immunotoxicity in Mice and Rats. J Immunotoxicol 3:227–244

    Article  CAS  PubMed  Google Scholar 

  36. Baken KA, Vandebriel RJ, Pennings JL et al (2007) Toxicogenomics in the assessment of immunotoxicity. Methods 41:132–141

    Article  CAS  PubMed  Google Scholar 

  37. Burns-Naas LA, Dearman RJ, Germolec DR et al (2006) Omics technologies and the immune system. Tox Mech Methods 16:101–119

    Article  CAS  Google Scholar 

  38. Baken KA, Arkusz J, Pennings JL et al (2007) In vitro immunotoxicity of bis(tri-n-butyltin)oxide (TBTO) studied by toxicogenomics. Toxicology 237:35–48

    Article  CAS  PubMed  Google Scholar 

  39. Ezendam J, Staedtler F, Pennings J et al (2004) Toxicogenomics of subchronic hexachlorobenzene exposure in Brown Norway rats. Environ Health Perspect 112:782–791

    CAS  PubMed  Google Scholar 

  40. Luebke RW, Holsapple MP, Ladics GS et al (2006) Immunotoxicogenomics: the potential of genomics technology in the immunotoxicity risk assessment process. Toxicol Sci 94:22–27

    Article  CAS  PubMed  Google Scholar 

  41. Van Loveren H, De Jong WH, Vandebriel RJ et al (1998) Risk assessment and immunotoxicology. Toxicol Lett 102–103:261–265

    Article  PubMed  Google Scholar 

  42. Van Loveren H, Slob W, Vandebriel RJ et al (1998) Immunotoxicology: extrapolation from animal to man–estimation of the immunotoxicologic risk associated with TBTO exposure. Arch Toxicol Suppl 20:285–292

    PubMed  Google Scholar 

  43. Brandon EF, Raap CD, Meijerman I et al (2003) An update on in vitro test methods in human hepatic drug biotransformation research: pros and cons. Toxicol Appl Pharmacol 189:233–246

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Laboratory for Health Protection Research, National Institute for Public Health and the Environment, 1, 3720, Bilthoven, BA, The Netherlands

    D. P. K. Lankveld, H. Van Loveren, K. A. Baken & R. J. Vandebriel

Authors
  1. D. P. K. Lankveld
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. H. Van Loveren
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. K. A. Baken
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. R. J. Vandebriel
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to R. J. Vandebriel .

Editor information

Editors and Affiliations

  1. College of Veterinary Medicine, Cornell University, Ithaca, 14853, U.S.A.

    Rodney R. Dietert

Rights and permissions

Reprints and permissions

Copyright information

© 2010 Humana Press, a part of Springer Science+Business Media, LLC

About this protocol

Cite this protocol

Lankveld, D.P.K., Van Loveren, H., Baken, K.A., Vandebriel, R.J. (2010). In Vitro Testing for Direct Immunotoxicity: State of the Art. In: Dietert, R. (eds) Immunotoxicity Testing. Methods in Molecular Biology™, vol 598. Humana Press. https://doi.org/10.1007/978-1-60761-401-2_26

Download citation

  • DOI: https://doi.org/10.1007/978-1-60761-401-2_26

  • Published:

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-60761-400-5

  • Online ISBN: 978-1-60761-401-2

  • eBook Packages: Springer Protocols

Publish with us

Policies and ethics

Search

Navigation